Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD
Haemophilia · 2024-01 · 30 (1) · 161-168
DOI: 10.1111/hae.14901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 27.11.2023. Verfasst von Jonathan C Roberts und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bleeding & Clotting Disorders Institute (BCDI), Peoria, Illinois, USA. Hauptthemen laut MEDLINE: von Willebrand Disease, Type 1, von Willebrand Diseases, von Willebrand Disease, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Takeda Pharmaceutical Company, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Introduction
VWD diagnosis is challenging requiring multiple VWF activity tests using many individual assays. We have developed an ELISA‐based VWF Multiplex Activity Assay (VWF‐MAA) to address this concern; however, the ability of the VWF‐MAA to discriminate between type 1 VWD, variant VWD, and normal subjects has not been evaluated.
Aim
To evaluate the VWF‐MAA and its ability to differentiate between type 1 VWD, variant VWD and normal subjects in individuals undergoing an initial laboratory evaluation for bleeding.
Methods
A total of 177 plasma samples from the Zimmerman Program: Comparative Effectiveness in the Diagnosis of VWD were evaluated from 11 centres across the US and Canada. The VWF‐MAA was compared to Versiti Blood Research Institute (VBRI) and Local Center (LC) assigned VWD diagnosis.
Results
Overall, 129/177 (72.9%) were correctly assigned as normal (non‐VWD), type 1, or variant VWD compared to the VBRI assigned diagnosis. VWF‐MAA assigned non‐VWD accurately in 29/57 (50.9%) samples, and type 1 VWD accurately in 93/110 (84.6%) samples. Considering LC diagnosis where there was agreement with VWF‐MAA and not VBRI diagnosis, type 1 VWD was accurate in 105/110 (95.5%) samples. Bland‐Altman analysis demonstrated good correlation between laboratory methods. VWD, types 2A, 2B, 1C VWD were also assigned by the VWF‐MAA.
Conclusions
We demonstrate that the VWF‐MAA has utility in differentiating type 1 VWD, variant VWD and normal subjects in individuals undergoing an initial laboratory evaluation for bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bleeding & Clotting Disorders Institute (BCDI), Peoria, Illinois, USA.
- Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA.
- Versiti Blood Research Institute (VBRI), Milwaukee, Wisconsin, USA.
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Jonathan C Roberts, Pamela A Christopherson, Michael D Tarantino
Förderung
- NHLBI NIH HHS
- Takeda Pharmaceutical Company
- National Heart, Lung, and Blood Institute
- World Federation of Hemophilia
Zitieren
APA
Roberts, J. C., Christopherson, P. A., Tarantino, M. D., Gonzales, S. E., Morateck, P. A., Perry, C. L., Flood, V. H., Abshire, T. C., Montgomery, R. R., & Zimmerman Program Investigators (2024). Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD. Haemophilia, 30(1), 161-168. https://doi.org/10.1111/hae.14901
Vancouver
Roberts JC, Christopherson PA, Tarantino MD, Gonzales SE, Morateck PA, Perry CL, et al. Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD. Haemophilia. 2024;30(1):161-168. doi:10.1111/hae.14901
BibTeX
@article{Roberts2024,
author = {Roberts, Jonathan C and Christopherson, Pamela A and Tarantino, Michael D and Gonzales, Sarah E and Morateck, Patti A and Perry, Crystal L and Flood, Veronica H and Abshire, Thomas C and Montgomery, Robert R and Zimmerman Program Investigators, Zimmerman Program Investigators},
title = {Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD},
journal = {Haemophilia},
year = {2024},
volume = {30},
number = {1},
pages = {161--168},
doi = {10.1111/hae.14901}
}
EUVIMED